Our Mission and Purpose
More R&D Pipelines
Specializing in the Discovery,
in R&D Pipeline
Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs, Haihe brings life-saving therapies to cancer patients worldwide.
Series B funding worth
1.2 billion yuan
Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Nuomaixi (Shanghai) Pharmaceutical Technology Co Ltd, and transferred the equities held by all shareholders to Shanghai Haihe Pharmaceutical Research and Development Co Ltd.
Haihe established its US office
Haihe’s Manufacturing Hub set foot in Taizhou Medical New & Hi-Tech Industrial Development Zone, with planned investment of 600 million yuan
Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise
The investigational drug paclitaxel oral formulation RMX 3001's Phase III clinicaltrial, which enrolled patients with advanced gastric cancer, completed the first dosing
Haihe completed Series A funding worth US$136.6 million
The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China
Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical
Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.
（Xinmin Evening News，2020-11-11）